Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation

References

• 1. Ojo AO, Hanson JA, Meier-Kriesche H et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J. Am. Soc. Nephrol. 12(3), 589–597 (2001).
  Medline CASGoogle Scholar
• 2. Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 50(1), 235–242 (1996).
  Medline CASGoogle Scholar
• 3. Browne BJ, Kahan BD. Renal transplantation. Surg. Clin. N. Am. 74(5), 1097–1116 (1994).
  Medline CASGoogle Scholar
• 4. Jain D, Haddad DB, Goel N. Choice of dialysis modality prior to kidney transplantation: does it matter? World J. Nephrol. 8(1), 1–10 (2019).
  MedlineGoogle Scholar
• 5. Lebranchu Y, Baan C, Biancone L et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl. Int. 27(2), 129–138 (2014).
  Medline CASGoogle Scholar
• 6. Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients. Transplant. Rev. 31(1), 47–54 (2017).
  Google Scholar
• 7. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9(Suppl. 3), S1–S155 (2009).
  MedlineGoogle Scholar
• 8. Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov. Today 20(10), 1243–1249 (2015).
  Medline CASGoogle Scholar
• 9. Morath C, Arns W, Schwenger V et al. Sirolimus in renal transplantation. Nephrol. Dial. Transplant. 22(Suppl. 8), viii61–viii65 (2007).
  Medline CASGoogle Scholar
• 10. Halleck F, Duerr M, Waiser J et al. An evaluation of sirolimus in renal transplantation. Expert Opin. Drug Metab. Toxicol. 8(10), 1337–1356 (2012).
  Medline CASGoogle Scholar
• 11. Shuang F, Zijie W, Hao C et al. Quadruple low-dose immunosuppressant maintenance therapy protocol in renal transplanted recipients within three months after renal transplantation. Chinese J. Organ Transplant. 41(03), 174–179 (2020).
  Google Scholar
• 12. Kirchner GI, Winkler M, Mueller L et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br. J. Clin. Pharmacol. 50(5), 449–454 (2000).
  Medline CASGoogle Scholar
• 13. Li Y, Yan L, Shi Y, Bai Y, Tang J, Wang L. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. Springer Plus 4, 637 (2015).
  MedlineGoogle Scholar
• 14. Tamashiro EY, Felipe CR, Genvigir FDV et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab. Pers. Ther. 32(2), 89–95 (2017).
  Medline CASGoogle Scholar
• 15. Santoro A, Felipe CR, Tedesco-Silva H et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12(9), 1293–1303 (2011).
  CASGoogle Scholar
• 16. Achour B, Barber J, Rostami-Hodjegan A. Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis. Drug Metab. Dispos. 42(8), 1349–1356 (2014).
  MedlineGoogle Scholar
• 17. Lolita L, Zheng M, Zhang X et al. The genetic polymorphism of CYP3A4 rs2242480 is associated with sirolimus trough concentrations among adult renal transplant recipients. Curr. Drug Metab. 21, 1–10 (2020).
  Google Scholar
• 18. Le Meur Y, Djebli N, Szelag JC et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80(1), 51–60 (2006).
  MedlineGoogle Scholar
• 19. Żochowska D, Wyzgał J, Pączek L. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann. Transplant. 17(3), 36–44 (2012).
  MedlineGoogle Scholar
• 20. Jones-Hughes T, Snowsill T, Haasova M et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess. 20(62), 1–594 (2016).
  Google Scholar
• 21. Cibulskis K, Lawrence MS, Carter SL et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol. 31(3), 213–219 (2013).
  Medline CASGoogle Scholar
• 22. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 296(5576), 2225–2229 (2002).
  Medline CASGoogle Scholar
• 23. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: where are we now and where are we going? Transplant Rev. (Orlando) 31(1), 10–17 (2017).
  MedlineGoogle Scholar
• 24. Lolodi O, Wang YM, Wright WC, Chen T. Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr. Drug Metab. 18(12), 1095–1105 (2017).
  Medline CASGoogle Scholar
• 25. Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm. Drug Dispos. 29(1), 1–5 (2008).
  Medline CASGoogle Scholar
• 26. Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Exp. Clin. Transplant. 13(Suppl. 1), 197–200 (2015).
  MedlineGoogle Scholar
• 27. Luo X, Zhu LJ, Cai NF, Zheng LY, Cheng ZN. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacologica Sinica 37(4), 555–560 (2016).
  Medline CASGoogle Scholar
• 28. Vannaprasaht S, Limwattananon C, Anutrakulchai S, Chan-On C. Effect of CYP3A5 genotype on hospitalization cost for kidney transplantation. Int. J. Clin. Pharm. 41(1), 88–95 (2019).
  Medline CASGoogle Scholar
• 29. Wang HF, Qiu F, Wu X et al. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. Clin. Pharmacol. Drug Dev. 3(3), 235–241 (2014).
  Medline CASGoogle Scholar
• 30. Djebli N, Rousseau A, Hoizey G et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin. Pharmacokinet. 45(11), 1135–1148 (2006).
  Medline CASGoogle Scholar